Research programme: chemokine receptor antagonists - ChemoCentryx

Drug Profile

Research programme: chemokine receptor antagonists - ChemoCentryx

Alternative Names: CCX 6239; CCX 9664; CCX 991; CCX-662; CCX650

Latest Information Update: 27 May 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ChemoCentryx
  • Class Small molecules
  • Mechanism of Action CCR2 receptor antagonists; CCR9 receptor antagonists; Chemokine receptor antagonists; CXCR4 receptor antagonists; CXCR7 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Metabolic disorders

Highest Development Phases

  • Preclinical Atopic dermatitis; Glioblastoma; Inflammatory bowel diseases; Psoriasis
  • No development reported Metabolic disorders

Most Recent Events

  • 12 May 2016 Preclinical development is still ongoing for Psoriasis in USA
  • 22 May 2014 Research programme: chemokine receptor antagonists - ChemoCentryx is available for licensing as of 22 May 2014. http://www.chemocentryx.com/
  • 22 May 2014 No development reported - Preclinical for Metabolic disorders in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top